stockrow
Friday 6 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +200.5%
Quarter to September 2026, against a year earlier
12.19
1.17
+10.62%
Follow VIR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 4 | 4 |
+8 more TTM periods Free account |
| (21.84%) | (26.08%) | (47.69%) | (45.73%) | ||
| (17.34%) | (20.91%) | (37.95%) | (36.47%) | ||
ROIC |
(30.32%) | (39.10%) | (88.19%) | (101.09%) | |
Return on Tangible Assets |
(38.87%) | (47.56%) | (88.09%) | (91.84%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.84) | (1.21) | (3.05) | (2.86) | |
Free Cash Flow |
(141.93) | (203.67) | (449.67) | (396.36) | |
Capital Expenditures |
(0.91) | (1.16) | (3.62) | (4.58) | |
| Other line items | |||||
Cash ROIC |
(10.46%) | (13.42%) | (34.83%) | (32.11%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.10 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 5,039.57 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
136.26% | 159.62% | 681.34% | 665.10% | |
Selling, General and Administrative Expense of Revenue |
33.55% | 32.77% | 139.66% | 134.30% | |
Share Based Compensation of Revenue |
15.24% | 15.51% | 71.91% | 71.58% | |
Operating CF/Net income |
0.76 | 0.80 | 1.01 | 0.89 | |
Depreciation/Fixed assets |
0.27 | 0.30 | 0.33 | 0.38 | |
Capex/Depreciation |
(0.07) | (0.08) | (0.21) | (0.22) | |
Revenue per Share |
1.79 | 1.81 | 0.44 | 0.49 | |
Operating CF per Share |
(0.83) | (1.21) | (3.03) | (2.83) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.06 | 0.07 |
Columns are period end dates · fundamentals updated 6 Nov 2026